GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » EV-to-Revenue

EXAS (Exact Sciences) EV-to-Revenue : 5.68 (As of Oct. 31, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Exact Sciences's enterprise value is $14,839 Mil. Exact Sciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $2,612 Mil. Therefore, Exact Sciences's EV-to-Revenue for today is 5.68.

The historical rank and industry rank for Exact Sciences's EV-to-Revenue or its related term are showing as below:

EXAS' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.57   Med: 14.65   Max: 1622.58
Current: 5.68

During the past 13 years, the highest EV-to-Revenue of Exact Sciences was 1622.58. The lowest was 3.57. And the median was 14.65.

EXAS's EV-to-Revenue is ranked worse than
69.59% of 217 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.14 vs EXAS: 5.68

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-10-31), Exact Sciences's stock price is $68.93. Exact Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $14.27. Therefore, Exact Sciences's PS Ratio for today is 4.83.


Exact Sciences EV-to-Revenue Historical Data

The historical data trend for Exact Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences EV-to-Revenue Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.30 14.49 8.41 5.10 6.08

Exact Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.14 5.89 6.08 5.76 3.68

Competitive Comparison of Exact Sciences's EV-to-Revenue

For the Diagnostics & Research subindustry, Exact Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Exact Sciences's EV-to-Revenue falls into.



Exact Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Exact Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=14839.278/2612.011
=5.68

Exact Sciences's current Enterprise Value is $14,839 Mil.
Exact Sciences's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,612 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exact Sciences  (NAS:EXAS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Exact Sciences's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=68.93/14.274
=4.83

Exact Sciences's share price for today is $68.93.
Exact Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exact Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Exact Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
Executives
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139